Takeda Pharmaceutical Co Ltd ADR
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $1,144,124,000 | $1,176,038,000 | $1,207,990,000 | $1,050,869,000 |
Gross Profit | 727,250,000 | 639,313,000 | 658,205,000 | 481,624,000 |
EBITDA | 380,278,000 | 384,548,000 | 187,278,000 | |
EBIT | 187,826,000 | 192,328,000 | 534,000 | |
Net Income | 23,789,000 | 92,046,000 | 95,248,000 | -3,018,000 |
Net Change In Cash | 1,144,124,000 | 1,176,038,000 | 1,207,990,000 | 1,050,869,000 |
Free Cash Flow | 327,105,000 | 209,526,000 | 21,577,000 | 208,148,000 |
Cash | 494,126,000 | 859,015,000 | 804,272,000 | 457,800,000 |
Basic Shares | 1,585,179 | 1,610,032 | 1,589,055 | 1,568,498 |
Annual Financials
| Values in thousands | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|
Revenue | $4,263,762,000 | $4,027,478,000 | $3,569,006,000 | $3,197,812,000 |
Gross Profit | 2,832,257,000 | 2,783,406,000 | 2,462,160,000 | 2,203,504,000 |
EBITDA | 874,601,000 | 1,184,514,000 | 1,183,213,000 | 983,718,000 |
EBIT | 146,599,000 | 520,114,000 | 600,062,000 | 424,047,000 |
Net Income | 144,067,000 | 317,017,000 | 230,059,000 | 376,005,000 |
Net Change In Cash | 4,263,762,000 | 4,027,478,000 | 3,569,006,000 | 3,197,812,000 |
Free Cash Flow | 235,614,000 | 343,467,000 | 937,068,000 | 774,463,000 |
Cash | 457,800,000 | 533,530,000 | 849,695,000 | 966,222,000 |
Basic Shares | 1,580,343 | 1,569,872 | 1,577,169 | 1,573,537 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $29.07 |
2024-06-30 | $0.19 |
2024-03-31 | -$0.006 |
2023-12-31 | $33.79 |
